Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In a rat model of chemotherapy-induced alopecia, this study found that low-level laser treatment significantly accelerated hair regrowth without affecting the efficacy of chemotherapy.

This study found that topical BPM31543 was safe, tolerable, and showed potential to reduce chemotherapy-induced alopecia at higher dosing levels among adult women with cancer receiving taxane-based chemotherapy.

This study found that applying BPM 31543 twice daily was safe, well-tolerated, and showed signs of reducing chemotherapy-induced alopecia in women receiving taxane-based chemotherapy.

This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.

This study reported that topical BPM31543 was safe and well-tolerated for patients on taxane-based chemotherapy, with some efficacy indicated in reducing hair loss at all dosages tested.

In this study involving women undergoing taxane-based chemotherapy, a twice-daily topical application of BPM31543 was well-tolerated and showed potential in reducing severe hair loss, prompting further investigation at higher doses.

This study found that a new treatment candidate may effectively prevent and promote recovery from chemotherapy-induced alopecia by normalizing apoptosis and reducing inflammation in cancer patients.

This review provides an overview of androgenetic alopecia, detailing its causes, diagnostic methods, and current treatments, noting that combination therapies show promise but newer options like cell-based treatments require more research.

This study reports that combination therapies, including surgical and various medical treatments, show promise for managing androgenetic alopecia, though further research is necessary to confirm the safety and effectiveness of emerging therapies.

This review discusses lifestyle interventions to manage weight and reduce metabolic consequences in women with PCOS but reports no new clinical results, highlighting the need for more randomized studies.

This study reviews the significant prevalence of organic etiologies, especially vascular causes, in erectile dysfunction among men under 40 and emphasizes thorough evaluation and consideration of treatment options like exercise and PDE-5 inhibitors.

This literature study reviews the consequences of hair loss due to chemotherapy and nursing care interventions but reports no new clinical results.

This review covers various strategies to manage chemotherapy-induced alopecia, highlighting that agents like AS101 and minoxidil can reduce its severity but not prevent it, with no new clinical results reported.

In a neonatal rat model, this study found that topical CDK2 inhibitors reduced chemotherapy-induced hair loss in 33 to 50% of the animals, suggesting a potential strategy for preventing alopecia in cancer patients.

This review examines dermatological side effects of taxane chemotherapy reported in past studies and highlights the necessity for identifying and managing these conditions to maintain cancer patients' quality of life; it presents no new clinical results.

This study found that scalp cooling significantly reduced the risk of chemotherapy-induced alopecia in breast cancer patients, while topical minoxidil and other interventions did not show significant efficacy.

This review discusses current knowledge and management strategies for chemotherapy-induced alopecia, highlighting the need for better research prioritization and providing patient support materials, but reports no new clinical results.

This study found that organ-cultured human scalp hair follicles can mimic chemotherapy-induced damage in vivo and serve as a model to explore molecular targets and protective agents for hair follicle preservation.

This article discusses a unique case of permanent chemotherapy-induced alopecia in a patient receiving chemotherapy for breast cancer, characterized by a distinctive histologic finding and excludes bone marrow transplantation, but reports no new clinical results.

This review discusses treatments for chemotherapy-induced alopecia, highlighting scalp cooling for hair loss prevention and 2% topical minoxidil for regrowth acceleration as effective options, but reports a need for more rigorous trials to validate promising new therapies.

This review discusses the incidence, reversibility, and impact of chemotherapy-induced alopecia and concludes that scalp cooling is the most effective prevention method in most cases, though some questions remain.

In this study, cisplatin was found to induce cell death in human hair follicle cells through hydroxyl radical generation and Bcl-2 down-regulation, suggesting potential strategies for preventing chemotherapy-induced alopecia.

This proposal reviews current knowledge and suggests actions for managing chemotherapy‐induced alopecia but reports no new clinical results, highlighting the need for evidence‐based guidelines.

This review discusses interventions for chemotherapy-induced hair loss and reports no new clinical results; scalp cooling and nutritional support are considered potential strategies but not yet substantiated.

This source reports that scalp cooling is currently the only safe and FDA-cleared method to potentially reduce chemotherapy-induced hair loss, with about a 50% chance of maintaining sufficient hair to avoid needing a wig.

In this study, researchers reported that the activation of EDA2R by p53 leads to p53-dependent cell death in cancer cells and is involved in chemotherapy-induced hair loss.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This review discusses chemotherapy-induced alopecia, highlighting its pathogenesis, clinical patterns, and current therapeutic approaches, with no new clinical results reported.

This article reviews trichoscopic signs of chemotherapy-induced alopecia, including exclamation marks, but reports no new clinical results.